↓ Skip to main content

Role of TET2 Mutations in Myeloproliferative Neoplasms

Overview of attention for article published in Current Hematologic Malignancy Reports, December 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 X users

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Role of TET2 Mutations in Myeloproliferative Neoplasms
Published in
Current Hematologic Malignancy Reports, December 2011
DOI 10.1007/s11899-011-0108-8
Pubmed ID
Authors

Elodie Pronier, François Delhommeau

Abstract

Recently, 5-hydroxymethylcytosine (5-hmC), the 6th base of DNA, was discovered as the product of the hydroxylation of 5-methylcytosine (5-mC) by the ten-eleven translocation (TET) oncogene family members. One of them, TET oncogene family member 2 (TET2), is mutated in a variety of myeloid malignancies, including in 15% of myeloproliferative neoplasms (MPNs). Recent studies tried to go further into the biological and epigenetic function of TET2 protein and 5-hmC marks in the pathogenesis of myeloid malignancies. Although its precise function remains partially unknown, TET2 appears to be an important regulator of hematopoietic stem cell biology. In both mouse and human cells, its inactivation leads to a dramatic deregulation of hematopoiesis that ultimately triggers blood malignancies. Understanding this leukemogenic process will provide tools to develop new epigenetic therapies against blood cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 2 5%
Denmark 1 3%
United States 1 3%
Unknown 35 90%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 33%
Researcher 8 21%
Other 3 8%
Student > Bachelor 3 8%
Student > Master 3 8%
Other 7 18%
Unknown 2 5%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 49%
Medicine and Dentistry 8 21%
Biochemistry, Genetics and Molecular Biology 6 15%
Unspecified 1 3%
Social Sciences 1 3%
Other 1 3%
Unknown 3 8%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2011.
All research outputs
#14,596,774
of 22,660,862 outputs
Outputs from Current Hematologic Malignancy Reports
#252
of 426 outputs
Outputs of similar age
#157,800
of 243,693 outputs
Outputs of similar age from Current Hematologic Malignancy Reports
#3
of 3 outputs
Altmetric has tracked 22,660,862 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 426 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 243,693 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.